Across TCGA pan-cancer cohorts, NDUFA13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NDUFA13 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher NDUFA13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NDUFA13 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, PDAC, and HNSC are the cancer types where NDUFA13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.916	0.639	.014	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
HNSC	DFS	Quartile	II,III,IV	0.818	0.970	.015	5	view →
CCRCC	DFS	Quartile	III,IV	0.078	0.740	.038	3	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NDUFA13 tumor-vs-normal RNA expression · all NDUFA13 data types